CRISPR Variant ThermoCas9 Offers Precision in Targeting Tumor DNA
A team of researchers from Wageningen University & Research and Van Andel Institute has introduced ThermoCas9, a CRISPR variant that precisely targets tumor DNA by recognizing methylation patterns. This breakthrough allows for the selective cleavage of cancerous DNA while leaving healthy cells intact. The study highlights ThermoCas9's ability to differentiate between methylated and unmethylated DNA, providing a new avenue for cancer treatment that minimizes harm to normal tissue. 
